НОВЫЕ ВОЗМОЖНОСТИ ТАРГЕТНОЙ ТЕРАПИИ МЕТАСТАТИЧЕСКОГО РАКА ПОЧКИ
Аннотация
Рассмотрены эффективность и переносимость Темсиролимуса у пациентов с метастатическим раком почки. Отмечены высокая противоопухолевая активность и хорошая переносимость препарата у больных распространенным почечно-клеточным раком с крайне неблагоприятным прогнозом, низкая частота развития побочных эффектов.
Об авторах
Б. Я. Алексеев
МНИОИ им. П.А. Герцена
Россия
Россия
А. С. Калпинский
МНИОИ им. П.А. Герцена
Россия
Россия
Список литературы
1. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74—108.
2. Чиссов В.И., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2007 году. М., 2008.
3. Godley P.A., Taylor M. Renal cell carcinoma. Curr Opin Oncol 2001;13:199—203.
4. Ravaud A., Debled M. Present achievements in the medical treatment of metastatic renal cell carcinoma. Crit Rev Oncol Hematol 1999;31:77—87.
5. US National Institutes of Health. Surveillance, Epidemiology and End Results (SEER) cancer statistics review: kidney and renal pelvis cancer; 5-yr relative survival rates, 1996—2002. Available at http://seer.cancer.gov/cgibin/csr/1975_2003/search.pl#results
6. Ljungberg B., Hanbury D.C., Kuczyk M.A. et al. Guidelines on renal cell cancer. European Association of Urology, 2009.
7. National Comprehensive Cancer Network, Cancer- and Treatment- Kidney Cancer. Practice Guidelines in Oncology, 2009. v. 1.
8. Yagoda A., Abi-Rached B., Petrylak D. Chemotherapy for advanced renal-cell carcinoma: 1983—1993. Semin Oncol 1995;22:42—60.
9. Mulders P. Continued progress in treatment of advanced renal cell carcinoma: an update on the role of Sunitinib. Eur Urol 2008;(Suppl 7):579—84.
10. Трапезникова М.Ф., Глыбин П.А., Морозов А.П. и др. Ангиогенные факторы при почечно-клеточном раке. Онкоурология 2008;(2):82—7.
11. Ravaud A., Wallerand H., Culine S. et al. Update on the medical treatment of metastatic renal cell carcinoma. Eur Urol 2008;54(2):315—25.
12. Hudson C.C., Liu M., Chiang G.G. et al. Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol Cell Biol 2002;22:7004—14.
13. Hay N., Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004;18:1926—45.
14. Pantuck A.J., Seligson D.B., Klatte T. et al. Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy. Cancer 2007;109:2257—67.
15. Patard J.-J. New treatment options for renal cell cancer critical evaluation. Eur Urol Suppl 2008;7(5):443—6.
16. Eisen T., Christmas T. Сlinical progress in Renal Cancer. London, 2007. p. 47—61, 173—91.
17. Patard J.-J. Tyrosine kinase inhibitors in clinical practice: patient selection. Eur Urol Suppl 2008;7:601—9.
18. Motzer R.J., Masumdar M., Bacic J. et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999;17(8):2530—40.
19. Motzer R.J., Bacik J., Murphy B.A. et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002;20(1):289—96.
20. Motzer R.J., Hutson T.E., Tomczak P. et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115—24.
21. Figlin R.A., Hutson T.E., Tomczak P. et al. Overall survival with Sunitinib versus interferon-alfa (IFN-α) as first-line treatment of metastatic renal cell carcinoma (mRCC). J Clin Oncol 2008;26(Suppl):256. Abstr. 5024.
22. Motzer R.J., Michaelson M.D., Hutson T.E. Sunitinib versus interferon alfa as first-line treatment of metastatic renal-cell carcinoma: updated efficacy and safety results and further analysis of prognostic factors. Eur J Cancer Suppl 2007;5:301. Abstr. 4509.
23. Raymond E., Alexandre J., Faivre S. et al. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol 2004;22:2336—47.
24. Rini B.I. Temsirolimus, an Inhibitor of Mammalian Target of rapamycin. Clin Cancer Res 2008;14;1286.
25. Peralba J.M., DeGraffenried L., Friedrichs W. et al. Pharmacodynamic evaluation of CCI-779, an inhibitor of mTOR, in cancer patients. Clin Cancer Res 2003;9:2887—92.
26. Brugarolas J., Lotan Y., Watumull L., Kabbani W. Sirolimus in metatastic renal cell carcinoma. J Clin Oncol 2008;26(20):3457—60.
27. Atkins M.B., Hidalgo M., Stadler W.M. et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004;22:909—18.
28. Hudes G., Carducci M., Tomczak P. et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356:2271—81.
29. Negrier S. Temsirolimus in metastatic renal cell carcinoma. Ann Onc 2008;19(8):1369—70.
30. Jac J., Giessinger S., Khan M. et al. A phase II trial of RAD001 in patients (Pts) with metastatic renal cell carcinoma (MRCC). Proc Am Soc Clin Oncol J Clin Oncol 2007;25:5107.
31. Motzer R.J., Escudier B., Oudard S. et al. Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled phase III trial. Lancet 2008;372:449—56.
32. Merchan J.R., Liu G., Fitch T. et al. Phase I/II trial of CCI-779 and bevacizumab in stage IV renal cell carcinoma: phase I safety and activity results. Proc Am Soc Clin Oncol J Clin Oncol 2007;25:5034.
33. Patnaik A., Ricart A., Cooper J. et al. A phase I, pharmacokinetic and pharmacodynamic study of sorafenib (S), a multi-targeted kinase inhibitor in combination with temsirolimus (T), an mTOR inhibitor in patients with advanced solid malignancies. Proc Am Soc Clin Oncol 2007;25:3512.
34. Motzer R.J., Figlin R.A., Hutson T.E. et al. Sunitinib versus interferon-alfa (IFN-{alpha}) as first-line treatment of metastatic renal cell carcinoma (mRCC): updated results and analysis of prognostic factors [meeting abstracts]. J Clin Oncol 2007;25:5024.
Для цитирования:
Алексеев Б.Я., Калпинский А.С. НОВЫЕ ВОЗМОЖНОСТИ ТАРГЕТНОЙ ТЕРАПИИ МЕТАСТАТИЧЕСКОГО РАКА ПОЧКИ. Онкоурология. 2009;5(3):8-12. https://doi.org/10.17650/1726-9776-2009-5-3-8-12
For citation:
Alekseyev B.Y., Kalpinsky A.S. NEW CAPACITIES OF TARGETED THERAPY FOR METASTATIC RENAL-CELL CARCINOMA. Cancer Urology. 2009;5(3):8-12. (In Russ.) https://doi.org/10.17650/1726-9776-2009-5-3-8-12
Просмотров: 448
Послать статью по эл. почте 
